Human placenta-derived cells(pda-001) for the treatment of adults with multiple sclerosis: Arandomized,placebo-controlled, multiple-dose study

Multiple Sclerosis and Related Disorders

Volumn 3, Issue 6, 2014, Pages 696-704

  Lublin, Fred D ^a   Bowen, James D ^b   Huddlestone, John ^c   Kremenchutzky, Marcelo ^d   Carpenter, Adam ^e   Corboy, John R ^f   Freedman, Mark S ^g   Krupp, Lauren ^h   Paulo, Corri ⁱ   Hariri, Robert J ⁱ   Fischkoff, Steven A ⁱ  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b SWEDISH MEDICAL CENTER   (United States)

^c Multicare Healthsystem   (United States)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g UNIVERSITY OF OTTAWA   (Canada)

^h STONY BROOK UNIVERSITY   (United States)

ⁱ CELGENE CORPORATION   (United States)

Author keywords

Cell therapy; Clinical trial; Immunomodulators; Mesenchymal stromal cells; Multiple sclerosis

Indexed keywords

4 AMINOPYRIDINE; AMANTADINE; AMITRIPTYLINE; BACLOFEN; BETA1A INTERFERON; CENPLACEL L; CYCLOBENZAPRINE; FINGOLIMOD; GABAPENTIN; GADOLINIUM; GLATIRAMER; HYDROCODONE BITARTRATE PLUS PARACETAMOL; MEDICAL CANNABIS; MODAFINIL; NALTREXONE; NATALIZUMAB; PLACEBO; PREDNISOLONE; PREGABALIN; TERIFLUNOMIDE; TIZANIDINE; CONTRAST MEDIUM;

ADULT; ANAPHYLAXIS; ARTICLE; CANADA; CLINICAL ARTICLE; CONTROLLED STUDY; DETERIORATION; DISEASE ACTIVITY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSESTHESIA; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEMALE; GAIT DISORDER; HEADACHE; HEMATOMA; HUMAN; LEG PAIN; LOW DRUG DOSE; MALE; MESENCHYME CELL; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE SPASM; NAUSEA; NEUROIMAGING; NEUROPATHIC PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PLACENTA; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RHINOPHARYNGITIS; SPASTICITY; SUPERFICIAL THROMBOPHLEBITIS; SWELLING; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; BRAIN; CLINICAL TRIAL; DIAGNOSTIC USE; DISABILITY; FOLLOW UP; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; BRAIN; CANADA; CONTRAST MEDIA; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

EID: 84928006514     PISSN: 22110348     EISSN: 22110356     Source Type: Journal    
DOI: 10.1016/j.msard.2014.08.002     Document Type: Article

References (23)

1. Bradley W. Neurology in clinical practice. 5th ed. Philadelphia, PA: Butterworth Heinemann Elsevier; 2008.
2. Chen J, Shehadah A, Pal A, Zacharek A, Cui X, Cui Y, et al. Neuroprotective effect of human placenta-derived cell treatment of stroke in rats. Cell Transplant 2013;22:871-9.
3. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17.
4. Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study. Lancet Neurol 2012;11:150-6.
5. Darlington PJ, Boivin MN, Bar-Or A. Harnessing the therapeutic potential of mesenchymal stem cells in multiple sclerosis. Expert Rev Neurother 2011;11:1295-303.
6. Fisher-Shoval Y, Barhum Y, Sadan O, Yust-Katz S, Ben-Zur T, Lev N, et al. Transplantation of placenta-derived mesenchymal stem cells in the EAE mouse model of MS. J Mol Neurosci 2012;48: 176-84.
7. He S, Khan J, Gleason J, Eliav E, Fik-Rymarkiewicz E, Herzberg U, et al. Placenta-derived adherent cells attenuate hyperalgesia and neuroinflammatory response associated with perineural inflammation in rats. Brain Behav Immun 2013;27:185-92.
8. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010;67: 1187-94.
9. Keough MB, Yong VW. Remyelination therapy for multiple sclerosis. Neurotherapeutics 2013;10:44-54.
10. Liang J, Zhang H, Hua B, Wang H, Wang J, Han Z, et al. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Mult Scler 2009;15:644-6.
11. Liu W, Morschauser A, Zhang X. Human placenta-derived adherent cells induce tolerogenic immune responses. Clin Transl Immunol 2014;3:e14. http://dx.doi.org/10.1038/cti.2014.5.
12. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11.
13. Martino G, Franklin RJ, Baron Van Evercooren A, Kerr DA. Stem cell transplantation in multiple sclerosis: current status and future prospects. Nat Rev Neurol 2010;6:247-55.
14. Mayer L, Pandak WM, Melmed GY, Hanauer SB, Johnson K, Payne D, et al. Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant crohn's disease: A phase 1 study. Inflamm Bowel Dis 2013;19:754-60.
15. Mohyeddin-Bonab M, Yazdanbakhsh S, Lotfi J, Alimoghaddom K, Talebian F, Hooshmand F, et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study Iran J Immunol 2007;4:50-7.
16. Morando S, Vigo T, Esposito M, Casazza S, Novi G, Principato MC, et al. The therapeutic effect of mesenchymal stem cell trans-plantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms. Stem Cell Res Ther 2012;3:3.
17. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007;110:3499-506.
18. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-6.
19. Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vecsei L, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006;13:700-22.
20. Riddell CA, Zhao Y, Li DK, Petkau AJ, Riddehough A, Cutter GR, et al. Evaluation of safety monitoring guidelines based on MRI lesion activity in multiple sclerosis. Neurology 2011;77:2089-96.
21. Rosati G. The prevalence of multiple sclerosis in the world: An update. Neurol Sci 2001;22:117-39.
22. Shehadah A, Chen J, Pal A, He S, Zeitlin A, Cui X, et al. Human placenta-derived adherent cell treatment of experimental stroke promotes functional recovery after stroke in young adult and older rats. PLoS One 2014;9:e86621.
23. Uccelli A, Laroni A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2011;10:649-56.